European Journal of Surgical Oncology
Volume 36, Issue 8 , Pages 718-724 , August 2010

Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: Comparison of five staging systems

,Accepted 17 May 2010.

References 

  1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74
  2. Abelev GI. Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv Cancer Res. 1971;14:295
  3. Alpert ME, Uriel J, de Nechaud B. Alpha-1 fetoglobulin in the diagnosis of human hepatoma. N Engl J Med. 1968;278:984
  4. Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395:19
  5. Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570
  6. Han SJ, Yoo S, Choi SH, et al. Actual half-life of alpha-fetoprotein as a prognostic tool in pediatric malignant tumors. Pediatr Surg Int. 1997;12:599
  7. The Cancer of the Liver Italian Program (CLIP) Investigators . A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998;28:751
  8. Zhang XF, Meng B, Qi X, et al. Prognostic factors after liver resection for hepatocellular carcinoma with hepatitis B virus-related cirrhosis: surgeon’s role in survival. Eur J Surg Oncol. 2009 Jun;35(6):622–628
  9. Hanazaki K, Kajikawa S, Koide N, et al. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol. 2001;96:1243
  10. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on cancer staging manual. 6th ed.. New York: Springer; 2002;p. 131–44
  11. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918
  12. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329
  13. Cho CS, Gonen M, Shia J, et al. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg. 2008;206:281
  14. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JIS score). J Gastroenterol. 2003;38:207
  15. Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither?. Am J Gastroenterol. 2006;101:524
  16. Murgita RA, Goidl EA, Kontianen S, et al. Alpha-fetoprotein induces suppressor T cells in vitro. Nature. 1977;267:257
  17. Yachnin S, Soltani K, Lester EP. Further studies on the mechanism of suppression of human lymphocyte transformation by human alpha-fetoprotein. J Allergy Clin Immunol. 1980;65:127
  18. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona – 2000 EASL conference. J Hepatol. 2001;35:421
  19. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519
  20. Orlandi F, Christensen E. A consensus conference on prognostic studies in hepatology. J Hepatol. 1999;30:171
  21. Llovet JM, Bruix J. Letter to the editor. Hepatology. 2000;32:679
  22. Marrero J, Fontana R, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707
  23. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44:723
  24. Chung H, Kudo M, Takahashi S, et al. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol. 2008;23:445
  25. Grieco A, Pompili M, Caminiti G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005;54:411
  26. Bruix J, Sherman M. Practice Guidelines Committee, American association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208
  27. Torzilli G, Donadon M, Marconi M, et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. Arch Surg. 2008;143:1082
  28. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002;20:1527

PII: S0748-7983(10)00130-7

doi: 10.1016/j.ejso.2010.05.022

European Journal of Surgical Oncology
Volume 36, Issue 8 , Pages 718-724 , August 2010

Article Tools

* Image Usage & Resolution